ALT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
-100.0%
26.0K
+420.0%
5.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
-100.0%
26.0K
+420.0%
5.0K
Operating Expenses
35.7M
+36.1%
26.2M
+8.2%
24.2M
-16.2%
28.9M
+38.6%
20.9M
R&D
27.0M
+44.8%
18.7M
+15.2%
16.2M
-12.0%
18.4M
+23.1%
15.0M
SG&A
8.7M
+14.7%
7.6M
-5.9%
8.1M
-23.4%
10.5M
+78.0%
5.9M
Operating Income
-35705000
-36.1%
-26229000
-8.2%
-24244000
+16.1%
-28893000
-38.5%
-20859000
EBITDA
-35694000
-36.2%
-26206000
-8.2%
-24221000
+16.1%
-28867000
-38.6%
-20832000
Net Income
-31608000
-38.5%
-22825000
-1.2%
-22563000
+17.5%
-27358000
-43.9%
-19014000
EPS (Basic)
$-0.15
-25.0%
$-0.12
+33.3%
$-0.18
+30.8%
$-0.26
-23.8%
$-0.21
EPS (Diluted)
$-0.15
-25.0%
$-0.12
+33.3%
$-0.18
+30.8%
$-0.26
-23.8%
$-0.21
Shares (Diluted)
205.3M
+10.7%
185.4M
+49.0%
124.5M
+17.4%
106.0M
+18.5%
89.4M
Altimmune (ALT) — Financials